Search Results for

GY023 (Suspended)

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

Continue Reading »

---

Search Again

• All Trial Categories Amyloidosis  (1) Bladder/Urinary Tract Cancer  (2)    Adjuvant  (1)    Metastatic  (1) Brain  (5)    Other Brain Tumors  (2) Breast  (8)    Breast Cancer Neoadjuvant  (2) Cancer Control/Symptom Management  (15) Colorectal Cancer  (1) Esophageal Cancer  (3) Gall Bladder/ Biliary Tract Cancer  (1) Gastric Cancer  (2) Head/Neck Cancer  (6) Leukemia  (2)    Acute Myeloid Leukemia (AML)  (1)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (1) Lung Cancer  (12)    Non-Small Cell Lung Cancer  (9)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (1)    Small Cell Lung Cancer  (3) Lymphoma  (3)    Non-Hodgkin’s Lymphoma  (3)       Diffuse Large B-Cell Lymphoma  (1)       Follicular Lymphoma  (2) MATCH Trial  (3) Melanoma  (3)    Metastatic  (1) Misc. Gynecology  (3) Multiple Myeloma  (1) Ovarian  (1) Pancreatic  (6)    Metastatic Disease  (1) Prostate  (9) Renal Cell/Kidney Cancer  (2) Sarcoma  (1) Thyroid  (1)